Amsterdam 2013 Programme Satellite Meetings Registration Exhibition Virtual Exhibition Hotels Visa Letter Invitation
Search Abstracts by author or title
(results will display both Free Papers & Poster)

Evaluation of corneal morphologic and functional parameters after use of oral isotretinoin in acne vulgaris

Poster Details

First Author: A.Demirok TURKEY

Co Author(s):    Y. Y?ld?r?m   A. Demircan   A. Basci   U. Celik   E. Bozkurt   Z. Kutlubay

Abstract Details


To report the effect of oral isotretinoin on corneal morphologic and functional parameters in patients with acne vulgaris.


Beyoglu Eye Training and Research Hospital ?stanbul,Turkey Cerrahpasa Medical Faculty of ?stanbul University Dermatology Department ?stanbul,Turkey


In this prospective and observational study 35 eyes of 35 patients who received oral isotretinoin for treatment of acne vulgaris were evaluated. Each clinical examination included a routine Schirmer I test and tear film break-up time (TBUT) was performed at baseline and after 1, 2, 3, and 6 months of treatment. Topographic measurements, including keratometry values, irregularity, and surface asymmetry index in the right eye of each participant were obtained using Scheimpflug camera with a Placido disc topographer (Sirius). Corneal hysteresis (CH), corneal resistance factor (CRF), corneal-compensated intraocular pressure (IOPcc) and Goldman-related intraocular pressure (IOPg) were measured using the Reichert Ocular Response Analyzer (ORA). Central corneal thickness (CCT) was also measured with ultrasonic pachymetry and the Sirius corneal topography system at baseline and after treatment


The Schirmer I test and TBUT were significantly decreased after treatment (for both; P<0.05). The CCT, topographical findings, and corneal biomechanical parameters were not significantly different at baseline and follow-up visits (P>0.05). No serious adverse effects were seen at follow up visits.


The study showed that oral isotretinoin caused no changes on corneal morphology and function.

Financial Disclosure:


Back to previous